INTRODUCTION: Site-selective imaging can provide significant insight into the mechanism of HIV-associated neurological disease. The goal of this study was to evaluate the involvement of serotonergic transmission in HIV-associated depression using [(11)C]DASB, a serotonin transporter (5-HTT)-specific radiopharmaceutical for positron emission tomography (PET). METHODS: Nine depressed HIV+ subjects (HIV-D), 9 non-depressed HIV+ subjects (HIV-ND) and 7 healthy controls (HC) underwent an MRI scan and a [(11)C]DASB-PET scan. The outcome measure was 5-HTT binding potential normalized to non-displaceable tissue radioligand (BP(ND)). RESULTS: HIV-ND subjects had lower mean regional 5-HTT BP(ND) estimates across regions compared to HC, while HIV-D subjects demonstrated higher mean regional binding values than HIV-ND subjects in most regions. Prior to correction for the false discovery rate, HIV-ND had significantly lower BP(ND) values compared to HC subjects in two regions (insula and anterior cingulate) and all HIV+ patients had significantly lower binding than HC in all regions except for the midbrain, thalamus and pons. After correction for the false discovery rate, only the insula showed significantly lower binding in HIV+ subjects compared to HC (P<0.0045). Despite a significant difference in the duration of illness between the HIV-D and HIV-ND groups, there was no definite correlation between the duration of illness and BP(ND). CONCLUSION: Lower [(11)C]DASB binding in HIV+ patients compared to HC may reflect serotonergic neuronal loss as a component of generalized HIV-associated neurodegeneration. Higher mean regional BP(ND) values in HIV-D compared to HIV-ND subjects could reflect increased density of 5-HTT, leading to increased clearance of serotonin from the synapse, which could account, in part, for symptoms of depression. The lack of correlation between duration of illness and binding argues against these findings being the result of differential neurodegeneration only. Our findings suggest a possible role for dysregulated serotonergic transmission in HIV-associated depression. Copyright (c) 2009 Elsevier Inc. All rights reserved.
INTRODUCTION: Site-selective imaging can provide significant insight into the mechanism of HIV-associated neurological disease. The goal of this study was to evaluate the involvement of serotonergic transmission in HIV-associated depression using [(11)C]DASB, a serotonin transporter (5-HTT)-specific radiopharmaceutical for positron emission tomography (PET). METHODS: Nine depressed HIV+ subjects (HIV-D), 9 non-depressedHIV+ subjects (HIV-ND) and 7 healthy controls (HC) underwent an MRI scan and a [(11)C]DASB-PET scan. The outcome measure was 5-HTT binding potential normalized to non-displaceable tissue radioligand (BP(ND)). RESULTS:HIV-ND subjects had lower mean regional 5-HTT BP(ND) estimates across regions compared to HC, while HIV-D subjects demonstrated higher mean regional binding values than HIV-ND subjects in most regions. Prior to correction for the false discovery rate, HIV-NDhad significantly lower BP(ND) values compared to HC subjects in two regions (insula and anterior cingulate) and all HIV+ patientshad significantly lower binding than HC in all regions except for the midbrain, thalamus and pons. After correction for the false discovery rate, only the insula showed significantly lower binding in HIV+ subjects compared to HC (P<0.0045). Despite a significant difference in the duration of illness between the HIV-D and HIV-ND groups, there was no definite correlation between the duration of illness and BP(ND). CONCLUSION: Lower [(11)C]DASB binding in HIV+ patients compared to HC may reflect serotonergic neuronal loss as a component of generalized HIV-associated neurodegeneration. Higher mean regional BP(ND) values in HIV-D compared to HIV-ND subjects could reflect increased density of 5-HTT, leading to increased clearance of serotonin from the synapse, which could account, in part, for symptoms of depression. The lack of correlation between duration of illness and binding argues against these findings being the result of differential neurodegeneration only. Our findings suggest a possible role for dysregulated serotonergic transmission in HIV-associated depression. Copyright (c) 2009 Elsevier Inc. All rights reserved.
Authors: Dara M Cannon; Masanori Ichise; Denise Rollis; Jacqueline M Klaver; Shilpa K Gandhi; Dennis S Charney; Husseini K Manji; Wayne C Drevets Journal: Biol Psychiatry Date: 2007-08-02 Impact factor: 13.382
Authors: Floris H P van Velden; Reina W Kloet; Bart N M van Berckel; Fred L Buijs; Gert Luurtsema; Adriaan A Lammertsma; Ronald Boellaard Journal: J Nucl Med Date: 2009-04-16 Impact factor: 10.057
Authors: Elizabeth P Hayden; Lea R Dougherty; Bryan Maloney; Thomas M Olino; Haroon Sheikh; C Emily Durbin; John I Nurnberger; Debomoy K Lahiri; Daniel N Klein Journal: J Affect Disord Date: 2007-09-04 Impact factor: 4.839
Authors: P Knekt; O Lindfors; T Härkänen; M Välikoski; E Virtala; M A Laaksonen; M Marttunen; M Kaipainen; C Renlund Journal: Psychol Med Date: 2007-11-16 Impact factor: 7.723
Authors: Michael Alan Horberg; Michael Jonah Silverberg; Leo Bartemeier Hurley; William James Towner; Daniel Benjamin Klein; Susan Bersoff-Matcha; Winkler Gabriel Weinberg; Diana Antoniskis; Miguel Mogyoros; Wayne Thomas Dodge; Robert Dobrinich; Charles Price Quesenberry; Drew Anthony Kovach Journal: J Acquir Immune Defic Syndr Date: 2008-03-01 Impact factor: 3.731
Authors: Clarisa M Buckner; Aimée J Luers; Tina M Calderon; Eliseo A Eugenin; Joan W Berman Journal: J Neuroimmune Pharmacol Date: 2006-04-13 Impact factor: 4.147
Authors: Kelly P Cosgrove; Julie K Staley; Ronald M Baldwin; Frederic Bois; Christophe Plisson; Mohammed S Al-Tikriti; John P Seibyl; Mark M Goodman; Gilles D Tamagnan Journal: Nucl Med Biol Date: 2010-05-06 Impact factor: 2.408
Authors: Uraina S Clark; Lawrence H Sweet; Susan Morgello; Noah S Philip; Ronald A Cohen Journal: Brain Imaging Behav Date: 2017-06 Impact factor: 3.978
Authors: Uraina S Clark; Keenan A Walker; Ronald A Cohen; Kathryn N Devlin; Anna M Folkers; Matthew J Pina; Karen T Tashima Journal: Neuropsychologia Date: 2015-03-03 Impact factor: 3.139